Merck (NYSE:MRK) received FDA approval for KEYTRUDA and its new subcutaneous formulation, KEYTRUDA QLEX, in combination therapies for platinum-resistant ovarian cancer. The approvals include a ...

Aethlon Medical, Inc. (NASDAQ:AEMD) Q3 2026 Earnings Call Transcript February 12, 2026 Aethlon Medical, Inc. misses on ...

AEMD READ THE FULL AEMD RESEARCH REPORT Cohort 2 participants being treated, with queue building for patient participation in trial Aethlon Medical (NASDAQ:AEMD) announced FY 3Q (quarter ended ...

Verified Market Research® indicates that the Global Intraocular Lens Market was valued at USD 4.46 Billion in 2024 and is projected to reach USD 6.53 Billion by 2032, expanding at a CAGR of 5.38% ...

Canada's health regulator has approved Merck's new under-the-skin version of its cancer drug Keytruda, offering an alternative to the current intravenous infusion. Health Canada has approved Keytruda ...

The U.S. Food and Drug Administration has approved a first-of-its-kind, noninvasive device, the Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer. Approval of ...

Three patients are suing Nura Pain Clinic saying they were severely injured after doctors placed spinal cord stimulators.

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billionFull Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions ...

The FDA has cleared a wearable device for adults with locally advanced pancreatic cancer that delivers low-intensity electric fields through adhesive patches placed on the skin. In the pivotal ...

The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment ...